Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Tanabe Stresses Enhancement of Competitiveness as Research-oriented Firm: President Hayama
October 21, 2002
- Fujisawa Introduces Atlas Data Suit from Gene Logic
October 21, 2002
- WORLD NEWS IN BRIEF
October 21, 2002
- Gov't-managed Health Insurance Posts Record-high Deficit
October 21, 2002
- Hisamitsu Licenses Keto Patch to Sigma-Tau in Italy
October 21, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 21, 2002
- Asahi Kasei to Spin Off 7 Divisions in October 2003
October 21, 2002
- The 3rd Kitasato Harvard Symposium Focuses on Global Drug Development
October 21, 2002
- BUSINESS NEWS IN BRIEF -1-
October 21, 2002
- Drug Organization Gives Grants to 5 Basic Research Projects
October 21, 2002
- Korosho Pledges to Smoothly Implement New Blood Law
October 14, 2002
- Korosho to Give Priority to Useful Drugs in Clinical Trial Consultation
October 14, 2002
- New ADR Information System under Investigation
October 14, 2002
- BUSINESS NEWS IN BRIEF
October 14, 2002
- WORLD NEWS IN BRIEF
October 14, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
October 14, 2002
- New Chugai Aims to Obtain 5% Market Share in 2005: President Nagayama
October 14, 2002
- Denka Seiken to Develop Tissue Culture Influenza Vaccines
October 14, 2002
- Suzuken Ends Acquisition of Ohmori to Regain the Top Position
October 14, 2002
- MPRF Invites Applications for Research Grants in Psychiatry
October 14, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…